Table 2:
CGRP targeting drugs: completed and ongoing trials.
| Drug name, type of molecule | Indication (acute or prophylactic) | Development stage | References for clinical trials (type of migraine, number of treated subjects) |
|---|---|---|---|
| Olcegepant (BIBN 4096 BS), CGRP antagonist |
Acute | Terminated for lack of oral availability | 112 (episodic, 126 subjects) |
| Telcagepant (MK-0974), CGRP antagonist |
Acute and prophylactic | Terminated for liver toxicity | 113 (episodic, 1068 subjects) 114 (episodic, 1294 subjects) 115 (episodic, 683 subjects) 116 (episodic, 660 subjects) 117 (episodic, 1380 subjects) 118 (episodic perimenstrual, 3960 subjects) 119 (episodic, 330 subjects) 120 (episodic, 1677 subjects) |
| MK-3207, CGRP antagonist |
Acute | Terminated for liver toxicity | 121 (episodic, 547 subjects) |
| BI 44370 TA, CGRP antagonist |
Acute | Terminated | 122 (episodic, 341 subjects) |
| Rimegepant (BMS-927711), CGRP antagonist |
Acute | Ongoing | 64 (episodic, 799 subjects) 65 (episodic, not available at this time) 66 (episodic, not available at this time) 67 (episodic, 1375 subjects) 123 (episodic, 1186 subjects) 124 (episodic, not available at this time) |
| Ubrogepant (MK-1602), CGRP antagonist |
Acute | FDA-approved | 60 (healthy, 518 subjects) 68 (episodic, 640 subjects) 69 (episodic, 1672 subjects) 70 (episodic, 1254 subjects) 125 (episodic, 1672 subject) 126 (episodic, 1465 subjects) |
| Atogepant (AGN-241689), CGRP antagonist |
Prophylactic | Ongoing | 72 (episodic, 825 subjects) 127 (episodic, not available at this time) 128 (episodic, not available at this time) 129 (chronic, not available at this time) 130 (episodic, not available at this time) |
| Fremanezumab (TEV48125), CGRP monoclonal antibody |
Prophylactic | FDA-approved | 74 (high frequency episodic, 296 subjects) 131 (chronic, 264 subjects) 132 (healthy, 139 subjects) 133 (episodic and chronic, 133 subjects) 134 (healthy, 64 subjects) 135 (episodic, 874 subjects) 136 (high frequency episodic and chronic, 297 subjects) 137 (chronic, 1130 subjects) |
| Galcanezumab (LY2951742), CGRP monoclonal antibody |
Prophylactic | FDA-approved | 76 (episodic, 217 subjects) 138 (healthy, 63 subjects) 139 (episodic, 410 subjects) 140 (episodic, 915 subjects) 141 (episodic, 410 subjects) 142 (episodic, 862 subjects) |
| Eptinezumab (ALD403), CGRP monoclonal antibody |
Prophylactic | Ongoing | 75 (frequent episodic, 174 subjects) 143 (chronic, 588 subjects) |
| Erenumab (AMG 334), CGRP receptor monoclonal antibody |
Prophylactic | FDA-approved | 77 (episodic, 483 subjects) 144 (episodic, 383 subjects) 145 (chronic, 667 subjects) 146 (healthy and episodic, 108 subjects) 147 (episodic, 577 subjects) 148 (episodic, 965 subjects) 149 (chronic, 667 subjects) |